A review of the scientific literature suggests the potential of caspase-4/5 as targets for a broad range of inflammatory diseases, including inflammatory bowel disease, hidradenitis suppurativa, and ...

Patients received placebo (Group 1), 50 mg golimumab (Group 2) or 100 mg golimumab (Group 3) subcutaneous injections every 4 weeks. Patients from Groups 1 and 2 with <20% improvement in tender/swollen ...

The Caspase 3 pipeline drugs market research report outlays comprehensive information on the Caspase 3 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of ...

The Caspase 2 pipeline drugs market research report outlays comprehensive information on the Caspase 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of ...

The retention of second-line golimumab was lower than that of first-line, but still favorable. Treatment persistence is favorable when golimumab is used as a long-term, first-line therapy among ...

Among patients with rheumatic diseases who discontinued treatment with non-tumor necrosis factor (TNF) inhibitors, approximately one-third continued to use golimumab as a third or subsequent line of ...

Roughly one-third of patients with rheumatic disease who discontinued use of non-TNF inhibitors continued treatment with golimumab as their third or subsequent line of therapy at 4 years. Among ...

Real-world data show the comparable safety and efficacy of golimumab with and without concomitant methotrexate for the treatment of RA. Improvements in disease activity were found to be comparable ...

Alvotech announced that a phase 1 pharmacokinetic study for its golimumab biosimilar referencing Simponi has commenced. Alvotech announced that it has begun dosing healthy participants with its ...